Laboratory Corporation of America Holdings
|Company Name||Laboratory Corporation of America Holdings|
On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, alleging that positive results on tests are incorrect about 85 percent of the time, and that patients who receive a positive result are supposed to pursue follow-up testing, which “can cost thousands of dollars, come with a small risk of miscarriage and can’t be performed until later in pregnancy.”
On this news, Labcorp’s stock fell $16.03, or 5%, to close at $298.18 per share on January 3, 2022, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Laboratory Corporation of America Holdings investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.